WALTHAM, Mass., Aug. 30, 2011 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel, biomarker-based diagnostics, announced today that results from subjects in the Prevention of Renal and Vascular End-stage Disease (PREVEND) study were presented at the European Society of Cardiology (ESC) Congress 2011, in Paris, France. The PREVEND study examined the association between levels of galectin-3 in blood and risk factors for cardiovascular disease and death in nearly 8,000 patients in the general population. Results demonstrated that galectin-3 levels are associated with risk factors for cardiovascular disease. Higher galectin-3 levels were associated with increased mortality rates in the study’s general patient population, underscoring the potential involvement of galectin-3 in cardiovascular disease. The results were featured in a presentation at ESC, “Galectin-3, Cardiovascular Risk Factors and Outcome in the General Population,” presented by Rudolf de Boer, MD, PhD, Associate Professor in Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands.
